Sisomicin
Sisomicin is a broad-spectrum aminoglycoside antibiotic produced by Micromonospora inyoensis. Sisomicin is highly active against Gram-positive bacteria[1][2].
Product Specifications
CAS Number
32385-11-8
Product Name Alternative
Antibiotic 6640; Rickamicin
UNSPSC
12352005
Hazard Statement
H312, H332, H360
Target
Antibiotic; Bacterial
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/sisomicin.html
Purity
98.45
Solubility
10 mM in DMSO
Smiles
O[C@@H]([C@@H]1O[C@@]2([H])OC(CN)=CC[C@H]2N)[C@H]([C@@H](C[C@@H]1N)N)O[C@](OC[C@](C)(O)[C@@H]3NC)([H])[C@@H]3O
Molecular Formula
C19H37N5O7
Molecular Weight
447.53
Precautions
H312, H332, H360
References & Citations
[1]Crowe CC, et al. Sisomicin: evaluation in vitro and comparison with gentamicin and tobramycin. Antimicrob Agents Chemother. 1973 Jan;3 (1) :24-8.|[2]P Noone, et al. Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use. Drugs. 1984 Jun;27 (6) :548-78.|[3]Le Moli S, et al. In vitro and in vivo effect of sisomicin and gentamycin on polymorphonuclear chemotaxis and phagocytosis. Int J Immunopharmacol. 1983;5 (1) :49-54.|[4]Fabre J, et al. Persistence of sisomicin and gentamicin in renal cortex and medulla compared with other organs and serum of rats. Kidney Int. 1976 Dec;10 (6) :444-9.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Aminoglycoside
Citation 01
ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|ACS Biomater Sci Eng. 2024 Apr 24.|Curr Microbiol. 2021 Dec 14;79 (1) :12.|Research Square Preprint. 2024 Apr 1.|STAR Protoc. 2024 Jun 7;5 (2) :103118.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC942879-500 1x 500 µL
Drebrin 1 (DBN1) (DBN1/2879), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
